Group 1 - Zurich Insurance Group has agreed to acquire ClearView Wealth for A$408.3 million (approximately $288.30 million) [1] - ClearView shareholders will receive a cash consideration of 65 Australian cents per share, representing a 21.5% premium to its last closing price [2]

SI-BONE (NasdaqGM:SIBN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAnshul Maheshwari - CFO and COOCaitlin Roberts - Director of MedTech Equity ResearchDavid Saxon - Managing DirectorLaura Francis - CEOMathew Blackman - Managing DirectorPatrick Wood - Managing DirectorSaqib Iqbal - VP of FP&A and Investor RelationsTravis Steed - Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood afternoon, and welcome to SI-BONE's fourth quarter 2025 earnings co ...

SI-BONE (NasdaqGM:SIBN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Company ParticipantsAnshul Maheshwari - CFO and COOCaitlin Roberts - Director of MedTech Equity ResearchDavid Saxon - Managing DirectorLaura Francis - CEOMathew Blackman - Managing DirectorPatrick Wood - Managing DirectorSaqib Iqbal - VP of FP&A and Investor RelationsTravis Steed - Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood afternoon, and welcome to SI-BONE's Fourth Quarter 2025 Earnings Co ...

SI-BONE (NasdaqGM:SIBN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Speaker5Good afternoon, and welcome to SI-BONE's fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Saqib Iqbal, Vice President, FP&A, and Investor Relations at SI-BONE, for a few introductory ...

SI-BONE Corporate Overview Recent Highlights – Record Performance Fourth Quarter 2025 Fiscal Year 2025 Note: Financial As of February 18, 2026 February 2026 Forward-Looking Statements The statements in this presentation regarding expectations of future events or results, including SI-BONE's expectations of continued revenue and procedure growth and financial outlook, are "forward-looking" statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve signific ...

Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (all comparisons are to the prior ...

Company Overview - SI-BONE, Inc. is a global leader in developing procedural solutions for clinical challenges related to compromised bone [3] - The company specializes in biomechanical design and innovations specific to anatomy, focusing on spinopelvic anatomy [3] - Since its inception in 2009, SI-BONE has supported over 140,000 procedures, backed by clinical evidence including four randomized controlled trials and over 180 peer-reviewed publications [3] Upcoming Events - SI-BONE will participate in the TD Cowen 46th Annual Health Care Conference in Boston, MA, hosting a fireside chat on March 2, 2026, at 7:30 a.m. Pacific Time [1] - Investors can listen to the conference call by registering through a provided link, with live audio available on the company's website [2]

Si-Bone (SIBN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 23, might help the stock move higher if these key numbers are better than expectat ...

Core Viewpoint - SI-BONE, Inc. is set to report its financial results for Q4 and the full year of 2025 on February 23, 2026, after market close, with a conference call scheduled for 1:30 p.m. Pacific Time [1] Company Overview - SI-BONE, Inc. is recognized as the global leader in developing procedural solutions for clinical challenges related to compromised bone [3] - The company specializes in additive manufacturing, leading to a technology platform with applications in SI joint fusion, adult spinal deformity, and pelvic trauma [3] - Since its inception in 2009, SI-BONE has facilitated over 140,000 procedures, supported by a robust body of clinical evidence including four randomized controlled trials and over 200 peer-reviewed publications [3]

Financial Performance - SI-BONE, Inc. announced preliminary unaudited revenue for Q4 2025 and the full year 2025, details to be provided in the attached press release[6] - The financial statements and exhibits related to the earnings report are included in the Form 8-K filing[8] Investor Relations - The company plans to meet with investors and analysts during the week of January 12, 2026, to discuss performance using presentation materials[7]